sfNopsis Minimum 
Strains of streptococci belonging to Lancefield group D, commonly called enterococci or faecal streptococci, differ markedly from other streptococci pathogenic to man by being relatively resistant to many commonly used antibiotics (Garrod, Lambert, and O'Grady, 1973) . Thus, Toala, McDonald, Wilcox, and Finland (1969) , who determined the sensitivities of some 382 strains of enterococci to 21 antibiotics, found that only ampicillin, benzylpenicillin, and vancomycin inhibited virtually all strains at a concentration of 6-3 jig/mn. The advent of several new cephalosporins in the past few years (Hamilton-Miller and Brumfitt, 1974) has raised the question as to whether any of these newer compounds show useful activity against enterococci, especially in view of two recent reports. The first of these, by Isenberg, Painter, Sampson-Scherer, and Siegel (1973) , suggests that, on the basis of disk tests, cephacetrile is considerably more active than cephalothin against group D streptococci, and the second is a statement (unsupported by any documentation) by Neiss (1973) that cephradine is more active than is cephalexin against enterococci. In view of the above, it was felt that a study of the antibacterial activity in vitro of established cephalosporins (cephalothin, cephaloridine, and (Cowan and Steel, 1965 (Cruickshank, 1968 Toala et al (1969) and Matsen and Coghlan (1972) . Sensitivity patterns of enterococci thus appear to be similar on each side of the Atlantic. Seneca (1973) , in a more recent survey of the activity of seven cephalosporins against organisms isolated from the urinary tract, confined his attention to Gramnegative organisms, so the present study supplements his. Our results confirm the two statements referred to in the introduction, that cephacetrile is more active than cephalothin, and cephradine than cephalexin, against enterococci, but the clinical significance of such facts is of extremely dubious significance, due to the high values of the MIC observed. Two further cephalosporins which have proceeded as far as pharmacokinetic studies in man are cephanone and cephapirin. We were unable to test these compounds, but other workers have shown that their activity against enterococci is akin to that of cephalothin (Axelrod, Meyers, and Hirschman, 1971; Meyers, Hirschman, and Nicholas, 1972) . Thus, none of the newer cephalosporins tested appear to show outstanding activity against enterococci, and none remotely approach ampicillin in this respect. Before dismissing these compounds, however, it is important to compare MICs with therapeutically attainable concentrations (table III) . From these figures it can be seen that serum antibiotic levels inhibitory to enterococci are likely to be attainable in vivo for cephaloridine, cefazolin, and cephanone, and possibly for cephacetrile as well. When urinary concentrations are considered an entirely different picture emerges; due to the relatively short half-lives of the cephalosporins in man, urinary excretion of a given dose is virtually complete after about six hours, so that average concentrations in the urine over this period can be expected to be of the order of 2 mg/ml after a 1 g dose. Such concentrations of any of the antibiotics tested here would be inhibitory for all the enterococci tested. Choice of treatment for infections of the biliary tract must take into account that, of the compounds tested, only cefazolin and ampicillin are excreted to any substantial degree in the bile.
For one specific enterococcal infection, subacute endocarditis, combination therapy with benzylpenicillin and streptomycin is favoured by clinicians (Standiford, de Maine, and Kirby, 1970) . Such a regimen may well be hazardous if the patient is allergic to penicillins, and the markedly lower incidence of reactions in such patients to cephalosporins makes the latter an attractive potential alternative (Simon, 1967) . On the basis of the findings in the present paper, a study of synergism between aminoglycosides on one hand, and cephaloridine, cefazolin, and cephanone on the other, may give valuable guidelines to alternative treatment regimens for systemic enterococcal infections in the penicillin-sensitive patient.
